6 papers in the library · 42 citations · publishing 2024-2025
J Psychoactive Drugs November 10, 2025 Nicky J. Mehtani, Maha N. Mian, Gabrielle Agin-Liebes et al. 1 citation
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
BMJ Open August 1, 2025 Nicky J. Mehtani, B. Anderson, Irina Alexander et al.
INTRODUCTION: Methamphetamine use disorder (MeUD) is a debilitating condition with no FDA-approved pharmacotherapies that has been associated with poor neurological, psychiatric and cardiovascular outcomes, particularly among low-income populations. The use of methamphetamine also increases risks for sexually transmitted infections (STIs) by reducing behavioural inhibitions while enhancing...
Nature Mental Health May 1, 2025 Daniel H. Grossman, Kevin R. Madden, Nicky J. Mehtani et al. 10 citations
Socioeconomic status (SES) substantially influences mental health outcomes and treatment access, yet its reporting in psychedelic-assisted therapy trials remains underexplored. Here we systematically reviewed 98 articles (49 primary trials and 49 secondary analyses) published between 2006 and 2024 examining classic psychedelics and MDMA for mental health conditions. Only 12% of primary trials...
Psychiatr Res Clin Pract February 11, 2025 Jules Evans, Marc Aixalà, Brian T Anderson et al. 18 citations
Objective: This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net. Methods: A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and safety. Results: The critical research gaps identified by the authors included defining the main types of psychedelic harm, the predictors...
Scientific Reports August 2, 2024 Jennifer Mitchell, Nicky J. Mehtani, Mallory O. Johnson et al. 9 citations
Abstract As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic , in part due to limited success...
Journal of Psychoactive Drugs 2024 Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani et al. 4 citations
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for...